Skip to main content
. Author manuscript; available in PMC: 2021 May 17.
Published in final edited form as: Am J Phys Med Rehabil. 2021 Jan 1;100(1):48–56. doi: 10.1097/PHM.0000000000001514

TABLE 2.

Summary of baseline clinical characteristics by LESI responders (>50% pain relief) vs. nonresponders that showed no differences between the two groups

Baseline Measure Responders
(n = 17)
Nonresponders
(n = 31)
P
Age, mean (SE) 52 (3) 49 (5) 0.47
BMI, mean (SE) 29.5 (1.9) 30.0 (1.5) 0.800
GATS total, mean (SE) 8.6 (2.8) 10.6 (2.0) 0.06
No. Patients (%) No. Patients (%)
Sex 0.24
 Male 8 (47) 14 (45)
 Female 9 (53) 17 (55)
Race 0.33
 Nonwhite 2 (12) 2 (6.5)
 White 15 (88) 29 (93.5)
Education 0.4
 High school 0 (0) 2 (6.5)
 >High school 17 (100) 29 (93.5)
Employed 0.2
 No 9 (53) 19 (61.3)
 Yes 8 (47) 12 (38.7)
Previous physical therapy 0.24
 No 14 (82.4) 23 (74.2)
 Yes 3 (17.6) 8 (25.8)
NSAIDs 0.6
 No 14 (82.4) 26 (83.9)
 Yes 3 (17.6) 5 (16.1)
Opioids 0.73
 No 13 (76.5) 25 (80.6)
 Yes 4 (23.5) 6 (19.4)
Neuropathic pain medications 0.25
 No 12 (70.6) 27 (87.1)
 Yes 5 (29.4) 4 (12.9)
Muscle relaxants 0.64
 No 16 (94) 27 (87.1)
 Yes 1 (6) 4 (12.9)

P values were obtained using independent-samples t test or Fisher’s exact test.

High school indicates some high school and high school graduate (or equivalent); >high school, some college or university, associate/bachelor’s degree, master’s degree, and doctorate/professional degree. NSAIDs reported included aspirin and ibuprofen. Opioids reported included hydrocodone-acetaminophen and oxymorphone. Neuropathic pain medications reported included amitriptyline, duloxetine, and gabapentin. Muscle relaxants reported included methocarbamol, cyclobenzaprine, carisoprodol, and baclofen.

BMI indicates body mass index; GATS, Global Adult Tobacco Survey; NSAID, nonsteroidal anti-inflammatory drug.